Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Current Signal: SELL (auto-tracking)
3.62% $15.73
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 1 270.99 mill |
EPS: | -2.29 |
P/E: | -6.87 |
Earnings Date: | Apr 30, 2024 |
SharesOutstanding: | 80.80 mill |
Avg Daily Volume: | 0.533 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -6.87 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.14x |
Company: PE -6.87 | industry: PE 47.78 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 15.08 - 16.38 ( +/- 4.14%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-15 | Sherman Matthew L | Buy | 17 275 | Common Stock |
2024-02-16 | Sherman Matthew L | Sell | 2 615 | Common Stock |
2024-02-15 | Sherman Matthew L | Buy | 69 100 | Stock Option (Right to Buy) |
2024-02-15 | Kelly Thomas Patrick | Buy | 17 275 | Common Stock |
2024-02-16 | Kelly Thomas Patrick | Sell | 3 010 | Common Stock |
INSIDER POWER |
---|
31.86 |
Last 99 transactions |
Buy: 6 983 334 | Sell: 3 513 431 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $15.73 (3.62% ) |
Volume | 0.764 mill |
Avg. Vol. | 0.533 mill |
% of Avg. Vol | 143.39 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $14.14 | N/A | Active |
---|
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.